👀Science Corp Receives EU Approval for PRIMA Vision Device
Millions Could Regain Sight with New Tech
TL;DR
Science Corporation's PRIMA device, approved by EU regulators, helps restore vision lost to age-related macular degeneration. Patients can read books and solve puzzles post-procedure.
Science Corp received approval from Europe’s medical device regulator for its PRIMA vision-restoring device. The device, which also has US FDA designation, could help millions regain functional sight after losing it due to age-related macular degeneration. Patients undergo a one-hour outpatient procedure to implant the chip and use camera-equipped glasses to see again. One patient finished a 300-page novel using PRIMA, highlighting its potential impact on daily life activities like reading and solving puzzles.
Key Points
PRIMA received CE mark from Europe’s medical regulator for treating age-related macular degeneration
US FDA granted a designation that's the first step toward expedited review of PRIMA in America
Each PRIMA device is expected to cost hundreds of thousands of dollars, making it pricey but potentially life-changing
Clinical trials were held in Germany; first procedure could happen as early as September
Science Corp aims to improve vision capabilities with a new chip and glasses version
Why It Matters
PRIMA offers functional vision restoration for patients suffering from age-related macular degeneration. One patient finished a 300-page novel post-procedure, showcasing the device's impact on daily activities like reading and solving puzzles. However, at hundreds of thousands of dollars per unit, cost-effectiveness remains a critical factor for healthcare providers considering reimbursement.
Frequently Asked Questions
Why does this matter?
PRIMA offers functional vision restoration for patients suffering from age-related macular degeneration. One patient finished a 300-page novel post-procedure, showcasing the device's impact on daily activities like reading and solving puzzles. However, at hundreds of thousands of dollars per unit, cost-effectiveness remains a critical factor for healthcare providers considering reimbursement.
What happened?
Science Corporation's PRIMA device, approved by EU regulators, helps restore vision lost to age-related macular degeneration. Patients can read books and solve puzzles post-procedure.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.